Insulin glargine biosimilars supposed to contribute 15% to total cost savings in overall biologic expenditures.
According to a 2015 study by RAND, insulin glargine biosimilars/follow-on agents were supposed to contribute 15% to total cost savings in overall biologic expenditures. This would be substantial, considering the size of the insulin marketplace, and their potential to slow increasing market shares from next-generation long-acting insulins.
But the savings may not be that quick to accrue. When Lilly introduces its version of insulin glargine (Basaglar) to the long-acting insulin market next month, what will the savings be? As a reminder, this product is not a biosimilar, according to its regulatory approval pathway, but a follow-on biologic, which means that it required more clinical trial data.
But the savings may not be that quick to accrue. When Lilly introduces its version of insulin glargine (Basaglar) to the long-acting insulin market next month, what will the savings be? As a reminder, this product is not a biosimilar, according to its regulatory approval pathway, but a follow-on biologic, which means that it required more clinical trial data. For example, Lilly conducted 2 Phase 3 studies (ELEMENT-1 and ELEMENT-2) with patients with types 1 and 2 diabetes mellitus, respectively) who had been treated prior to enrolling in the investigation. Furthermore, design and development costs of the pen-delivery device must be considered.
On this basis, one should not expect more than 15% discounts off of wholesale acquisition cost. This does not consider possible rebates and individual contracts made with CVS Health and OptumRx to prefer Basaglar and exclude Lantus® from coverage. However, it does seem reasonable that additional versions of insulin glargine will need to enter the marketplace before general discounts are commonly seen.
When might this occur? The next drug up for approval is a result of the Merck—Samsung Bioepis collaboration. On August 5, 2016, the FDA accepted their application for 351(a) approval of MK-1293. They also filed for biosimilar approval in Europe earlier this year, with the hope of receiving positive news from the EMA before the end of the year.
On November 3, 2016, Biocon and Mylan submitted its application to the European Medicines Agency (EMA) for a biosimilar to insulin glargine. Lilly had submitted its drug as a biosimilar as well to the EMA, and as a result, it is already available in the EU. There is no word as of yet when Biocon/Mylan’s 351(a) application will be submitted to the FDA. Its 500-patient phase 3 study of this product versus Lantus® in patients with type 1 diabetes was completed in June 2016. Its 600-patient phase 3 investigation in patients with type 2 diabetes was estimated to be completed in June as well. An open-label extension study of the agent is underway and will be finished in March 2017. This seems to support—assuming positive results, of course—a regulatory submission no earlier than Q4 2017.
Therefore, it may be late 2018 before 3 follow-on insulin glargine products are actively competing with Lantus® and its next-generation insulin glargine brand. By that time, discounts and rebates may mean savings of 30% or more, as the category becomes saturated, to nearly commodity levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.